CCND1 and cancer: Our discovery that obatoclax targets cyclin D1 for degradation provides a novel insight into the anticancer mechanisms of obatoclax, but also identifies a potential application of obatoclax for the therapeutic ablation of cyclin D1 to treat the cancers addicted to aberrant cyclin D1 overexpression.